Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969968700> ?p ?o ?g. }
- W2969968700 endingPage "124" @default.
- W2969968700 startingPage "124" @default.
- W2969968700 abstract "Immune suppressed renal transplant patients are more prone to developing oral tissue alterations due to medications associated with a pleiotropic set of side effects involving the oral cavity. Drug-induced gingival overgrowth (DIGO) is the most commonly encountered side effect resulting from administration of calcineurin inhibitors such as cyclosporine-A (CsA), the standard first-line treatment for graft rejection prevention in transplant patients. Pathogenesis of gingival overgrowth (GO) is determined by the interrelation between medications and a pre-existing inflammatory periodontal condition, the main modifiable risk factor. Severity of gingival hyperplasia clinical manifestation is also related to calcium channel blocker association, frequently provided in addition to pharmacological therapy of transplant recipients. Specifically, nifedipine-induced enlargements have a higher prevalence rate compared to amlodipine-induced enlargements; 47.8% and 3.3% respectively. Available epidemiological data show a gender difference in prevalence, whereby males are generally more frequently affected than females. The impact of GO on the well-being of an individual is significant, often leading to complications related to masticatory function and phonation, a side effect that may necessitate switching to the tacrolimus drug that, under a similar regimen, is associated with a low incidence of gingival lesion. Early detection and management of GO is imperative to allow patients to continue life-prolonging therapy with minimal morbidity. The purpose of this study was threefold: firstly, to determine the prevalence and incidence of GO under the administration of CsA and Tacrolimus; secondly, to assess the correlation between periodontal status before and after periodontal therapy and medications on progression or recurrence of DIGO; and finally, to analyse the effect of immunosuppressant in association to the channel blocker agents on the onset and progression of gingival enlargement. We compared seventy-two renal transplant patients, including 33 patients who were receiving CsA, of which 25% were also receiving nifedipine and 9.72% also receiving amlodipine, and 39 patients who were receiving tacrolimus, of which 37.5% were also receiving nifedipine and 5.55% also receiving amlodipine, aged between 35 and 60 years. Medical and pharmacological data were recorded for all patients. Clinical periodontal examination, in order to establish the inflammatory status and degree of gingival enlargement, was performed at baseline (T0), 3 months (T1), 6 months (T2), and 9 months (T3). All patients were subjected to periodontal treatment. Statistically significant correlation between the reduction of the mean value of periodontal indices and degree of gingival hyperplasia at the three times was revealed. The prevalence of GO in patients taking cyclosporine was higher (33.3%) in comparison with those taking tacrolimus (14.7%). In accordance with previous studies, this trial highlighted the clinical significance of the pathological substrate on stimulating drug-induced gingival lesion, confirming the key role of periodontal inflammation in pathogenesis of gingival enlargement, but did not confirm the additional effect of calcium-channel blocker drugs in inducing gingival enlargement." @default.
- W2969968700 created "2019-08-29" @default.
- W2969968700 creator A5001288941 @default.
- W2969968700 creator A5003792842 @default.
- W2969968700 creator A5011456703 @default.
- W2969968700 creator A5020789153 @default.
- W2969968700 creator A5025407753 @default.
- W2969968700 creator A5029196758 @default.
- W2969968700 creator A5035157515 @default.
- W2969968700 creator A5040961611 @default.
- W2969968700 creator A5045965638 @default.
- W2969968700 creator A5051869566 @default.
- W2969968700 creator A5074561273 @default.
- W2969968700 date "2019-08-21" @default.
- W2969968700 modified "2023-10-02" @default.
- W2969968700 title "Periodontal Microbiological Status Influences the Occurrence of Cyclosporine-A and Tacrolimus-Induced Gingival Overgrowth" @default.
- W2969968700 cites W1532677656 @default.
- W2969968700 cites W157413753 @default.
- W2969968700 cites W1965509702 @default.
- W2969968700 cites W1988909100 @default.
- W2969968700 cites W1996248247 @default.
- W2969968700 cites W2017797465 @default.
- W2969968700 cites W2025558495 @default.
- W2969968700 cites W2025999474 @default.
- W2969968700 cites W2027851005 @default.
- W2969968700 cites W2033782118 @default.
- W2969968700 cites W2036159342 @default.
- W2969968700 cites W2048318052 @default.
- W2969968700 cites W2053526836 @default.
- W2969968700 cites W2067518187 @default.
- W2969968700 cites W2074619321 @default.
- W2969968700 cites W2082833973 @default.
- W2969968700 cites W2100637508 @default.
- W2969968700 cites W2101829842 @default.
- W2969968700 cites W2107998968 @default.
- W2969968700 cites W2127318201 @default.
- W2969968700 cites W2134100814 @default.
- W2969968700 cites W2134498517 @default.
- W2969968700 cites W2149706668 @default.
- W2969968700 cites W2167435614 @default.
- W2969968700 cites W2169220031 @default.
- W2969968700 cites W2186151193 @default.
- W2969968700 cites W2317649312 @default.
- W2969968700 cites W2341062355 @default.
- W2969968700 cites W2399165565 @default.
- W2969968700 cites W2409116042 @default.
- W2969968700 cites W2517683945 @default.
- W2969968700 cites W2554700820 @default.
- W2969968700 cites W2555023167 @default.
- W2969968700 cites W2563494459 @default.
- W2969968700 cites W2589184080 @default.
- W2969968700 cites W2593285226 @default.
- W2969968700 cites W2730465681 @default.
- W2969968700 cites W2734366723 @default.
- W2969968700 cites W2775706477 @default.
- W2969968700 cites W2794798475 @default.
- W2969968700 cites W2795629497 @default.
- W2969968700 cites W2904084059 @default.
- W2969968700 cites W2947742064 @default.
- W2969968700 cites W2952789402 @default.
- W2969968700 cites W2991021120 @default.
- W2969968700 cites W3021464183 @default.
- W2969968700 cites W3025588588 @default.
- W2969968700 cites W46952399 @default.
- W2969968700 doi "https://doi.org/10.3390/antibiotics8030124" @default.
- W2969968700 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6784123" @default.
- W2969968700 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31438651" @default.
- W2969968700 hasPublicationYear "2019" @default.
- W2969968700 type Work @default.
- W2969968700 sameAs 2969968700 @default.
- W2969968700 citedByCount "24" @default.
- W2969968700 countsByYear W29699687002019 @default.
- W2969968700 countsByYear W29699687002020 @default.
- W2969968700 countsByYear W29699687002021 @default.
- W2969968700 countsByYear W29699687002022 @default.
- W2969968700 countsByYear W29699687002023 @default.
- W2969968700 crossrefType "journal-article" @default.
- W2969968700 hasAuthorship W2969968700A5001288941 @default.
- W2969968700 hasAuthorship W2969968700A5003792842 @default.
- W2969968700 hasAuthorship W2969968700A5011456703 @default.
- W2969968700 hasAuthorship W2969968700A5020789153 @default.
- W2969968700 hasAuthorship W2969968700A5025407753 @default.
- W2969968700 hasAuthorship W2969968700A5029196758 @default.
- W2969968700 hasAuthorship W2969968700A5035157515 @default.
- W2969968700 hasAuthorship W2969968700A5040961611 @default.
- W2969968700 hasAuthorship W2969968700A5045965638 @default.
- W2969968700 hasAuthorship W2969968700A5051869566 @default.
- W2969968700 hasAuthorship W2969968700A5074561273 @default.
- W2969968700 hasBestOaLocation W29699687001 @default.
- W2969968700 hasConcept C120665830 @default.
- W2969968700 hasConcept C121332964 @default.
- W2969968700 hasConcept C126322002 @default.
- W2969968700 hasConcept C128057223 @default.
- W2969968700 hasConcept C199343813 @default.
- W2969968700 hasConcept C199360897 @default.
- W2969968700 hasConcept C2779066535 @default.
- W2969968700 hasConcept C2780090536 @default.
- W2969968700 hasConcept C2909675724 @default.